Matches in Wikidata for { <http://www.wikidata.org/entity/Q37216260> ?p ?o ?g. }
- Q37216260 description "article científic" @default.
- Q37216260 description "article scientifique" @default.
- Q37216260 description "articolo scientifico" @default.
- Q37216260 description "artigo científico" @default.
- Q37216260 description "artículu científicu espublizáu en 2016" @default.
- Q37216260 description "bilimsel makale" @default.
- Q37216260 description "bài báo khoa học" @default.
- Q37216260 description "scientific article published on 14 January 2016" @default.
- Q37216260 description "vedecký článok" @default.
- Q37216260 description "vetenskaplig artikel" @default.
- Q37216260 description "videnskabelig artikel" @default.
- Q37216260 description "vědecký článek" @default.
- Q37216260 description "wetenschappelijk artikel" @default.
- Q37216260 description "wissenschaftlicher Artikel" @default.
- Q37216260 description "наукова стаття, опублікована в січні 2016" @default.
- Q37216260 description "научни чланак" @default.
- Q37216260 description "مقالة علمية نشرت في 14 يناير 2016" @default.
- Q37216260 name "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 name "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 name "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 type Item @default.
- Q37216260 label "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 label "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 label "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 prefLabel "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 prefLabel "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 prefLabel "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 P1433 Q37216260-42E1F118-CA2F-45D5-BDB4-757DB8E53C28 @default.
- Q37216260 P1476 Q37216260-4C2408E7-0CA9-450C-8447-BD3CD9DB7CD8 @default.
- Q37216260 P2093 Q37216260-2DE61D78-ADE6-4AFA-9520-9BE5C0FD1BF3 @default.
- Q37216260 P2093 Q37216260-54616753-33D3-4D65-B859-4BCF73DABD06 @default.
- Q37216260 P2093 Q37216260-6250C3D0-2C03-4628-B1C0-A6944FEF2C95 @default.
- Q37216260 P2093 Q37216260-685E963D-3AFD-4E94-B59B-2C5538D8EB51 @default.
- Q37216260 P2093 Q37216260-75DB13F9-9C6A-4B02-BD2C-36D823F86AC4 @default.
- Q37216260 P2093 Q37216260-785130BB-06ED-457B-AF34-2DE9F1B0F817 @default.
- Q37216260 P2093 Q37216260-80654986-9C64-406D-A86A-AD72CEFDA5A7 @default.
- Q37216260 P2093 Q37216260-A0E898D3-C7AD-4FAB-ACFF-FBEE94DC2AE6 @default.
- Q37216260 P2093 Q37216260-A53C1FEF-75F7-4C45-8F92-15935B486BE0 @default.
- Q37216260 P2093 Q37216260-BEFB23B5-499E-406A-9428-A8C7DD9F43EC @default.
- Q37216260 P2093 Q37216260-DACF3491-3A1E-48E3-A24D-93FEE292FB05 @default.
- Q37216260 P2093 Q37216260-E754D4F1-6AE3-45FB-BC18-721BB0567140 @default.
- Q37216260 P2093 Q37216260-F2957AB0-4A27-443D-A86F-270A1769D192 @default.
- Q37216260 P2860 Q37216260-00DA97F0-861D-456A-BB39-134001C3A6D7 @default.
- Q37216260 P2860 Q37216260-5721E9AD-4A2B-48C9-82E8-7F7BC40B0F82 @default.
- Q37216260 P2860 Q37216260-6A9AFBBE-69A3-4E6E-A6F4-3BD282BA3E30 @default.
- Q37216260 P2860 Q37216260-6FF9D761-BEB2-4F34-A35F-22460D97EAFB @default.
- Q37216260 P2860 Q37216260-754A22FA-9371-415A-BC9A-574E577B6073 @default.
- Q37216260 P2860 Q37216260-76148D31-6D35-49C2-8961-0A0EF2589908 @default.
- Q37216260 P2860 Q37216260-76A38A15-F07A-4584-B30F-44F0A70EADD1 @default.
- Q37216260 P2860 Q37216260-7756300C-EE50-4123-8C25-A2C24657CAAC @default.
- Q37216260 P2860 Q37216260-7D13337D-1FA5-425D-8990-3F3D7FE19603 @default.
- Q37216260 P2860 Q37216260-8951A3F3-D9F0-4195-99BC-4CFA1A7E533E @default.
- Q37216260 P2860 Q37216260-8980D94A-F736-4983-A6D6-7F0FD5EC51E4 @default.
- Q37216260 P2860 Q37216260-91E243A6-A740-4203-A1A7-94AC92521889 @default.
- Q37216260 P2860 Q37216260-9CF8DF7D-7C17-430F-8D26-185EDC97ADBD @default.
- Q37216260 P2860 Q37216260-D13D6142-F71F-42F5-A082-6D5E84ECCE77 @default.
- Q37216260 P2860 Q37216260-D1A13ECF-8BDB-437C-BC1C-CAE3035D3B2A @default.
- Q37216260 P2860 Q37216260-D3065DCD-8862-48CA-9FCB-B0D13709A989 @default.
- Q37216260 P2860 Q37216260-D48CBA91-96EF-4D0E-BA22-8095B2B09820 @default.
- Q37216260 P2860 Q37216260-D615ED1F-AC8D-40B4-ACFA-177222C91526 @default.
- Q37216260 P2860 Q37216260-D914F0FE-18FF-40BE-8237-17D164337C69 @default.
- Q37216260 P2860 Q37216260-E8E1D0D8-6EFA-4C2D-86D2-9BC20DC37EF7 @default.
- Q37216260 P2860 Q37216260-FFD1DD23-D610-4F95-9C33-CA47C5D6CD23 @default.
- Q37216260 P304 Q37216260-C76764E6-7C8E-49EB-B585-0E9D3FA9C087 @default.
- Q37216260 P31 Q37216260-F5DB107D-E27A-4AD6-A5B3-3B7757946FE3 @default.
- Q37216260 P356 Q37216260-70C07F5F-9CB3-44E7-AA35-0C08D5B072B4 @default.
- Q37216260 P407 Q37216260-BFD171D1-F6F7-44CB-A644-6E5F49960975 @default.
- Q37216260 P433 Q37216260-315F7CDF-F886-497E-8A6F-C25FBDC63457 @default.
- Q37216260 P478 Q37216260-ADA1D4E9-3FE8-49A4-A0B1-DC380885603A @default.
- Q37216260 P50 Q37216260-C5BCA2A4-4C8B-47BB-AE9A-5C96FF904F03 @default.
- Q37216260 P577 Q37216260-EFB3ECB4-FDF3-480A-A258-70BABB6DFADD @default.
- Q37216260 P5875 Q37216260-8367C46A-1CC4-46A0-8920-5FB4FD4FEFE5 @default.
- Q37216260 P698 Q37216260-E852A320-6A81-4C51-9A89-F93A4352A3B5 @default.
- Q37216260 P921 Q37216260-92818138-879E-4EE6-B46D-38408F78EF2E @default.
- Q37216260 P932 Q37216260-6D4667D3-E442-4924-8051-7C016545D90A @default.
- Q37216260 P356 HAEMATOL.2015.134213 @default.
- Q37216260 P698 26768687 @default.
- Q37216260 P1433 Q5638209 @default.
- Q37216260 P1476 "Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program" @default.
- Q37216260 P2093 "Aspasia Stamatoullas" @default.
- Q37216260 P2093 "Aurore Perrot" @default.
- Q37216260 P2093 "Cécile Borel" @default.
- Q37216260 P2093 "Emmanuelle Nicolas-Virelizier" @default.
- Q37216260 P2093 "Franck Morschhauser" @default.
- Q37216260 P2093 "Hélène Monjanel" @default.
- Q37216260 P2093 "Krimo Bouabdallah" @default.
- Q37216260 P2093 "Lymphoma Study Association (LYSA)" @default.
- Q37216260 P2093 "Marc Bernard" @default.
- Q37216260 P2093 "Marion Fournier" @default.
- Q37216260 P2093 "Pauline Brice" @default.
- Q37216260 P2093 "Philippe Quittet" @default.
- Q37216260 P2093 "Réda Bouabdallah" @default.
- Q37216260 P2860 Q27022992 @default.
- Q37216260 P2860 Q33400803 @default.
- Q37216260 P2860 Q33405002 @default.
- Q37216260 P2860 Q33420273 @default.
- Q37216260 P2860 Q33773306 @default.
- Q37216260 P2860 Q34147803 @default.
- Q37216260 P2860 Q34325201 @default.
- Q37216260 P2860 Q35103536 @default.